

Lupin launches Molnupiravir under brand name Molnulup

07 January 2022 | News

Clinical data suggests that it is effective on patients with co-morbidities



Lupin has launched Molnupiravir in India under the brand name Molnulup. This drug has been given emergency use authorisation by the Drug Controller General of India (DCGI) for treatment of adult patients with COVID-19, with SpO₂ > 93 per cent, and the ones who have a high risk of progression of the disease including hospitalisation.

Internationally, Molnupiravir is an oral antiviral that has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the US Food and Drug Administration (FDA) for the treatment of mild-to-moderate cases of COVID-19 in adults.

Administered orally, Molnupiravir inhibits the replication of SARS-CoV-2, the causative agent of COVID-19. Pre-clinical and clinical data have shown Molnupiravir to be effective against the most common SARS-CoV-2 variants including Gamma, Delta, and Mu variants. Molnupiravir should be initiated as soon as possible after a diagnosis of COVID-19 and within five days of onset of symptoms.